Ascentage Pharma management to join Citi Biopharma Back to School investor conferencePUBT·2 days ago, 12:06 PMAAPG+1.53%06855+1.74%
Cross-Border Tension and Endogenous Recovery: The New Divide in Hong Kong EquitiesGlobal Report·Sep 1 at 11:33 AM09898+0.66%09858+7.89%
AI pivots, a 7th price hike, and literal gold: Inside a fractured marketGlobal Report·Sep 1 at 09:18 AM06960-0.22%02013+0.52%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Aug 27 at 12:05 PMACIU-3.38%VNRX-2.77%
Biopharma's Global Push and Boardroom Shakeups Across HK EquitiesGlobal Report·Aug 25 at 11:32 AM06855+1.74%01541+0.29%
HK Diversified Equities Restructure: Key Signals in Tech and OperationsGlobal Report·Aug 25 at 09:21 AM01833+4.39%02689-0.75%
Jeet Mukherjee Initiates Buy on Ascentage Pharma, Citing 2027 NRDL Lisaftoclax Catalyst, Late‑Stage Pipeline Readouts, and Cash Runway Through 2027Tip Ranks·Aug 21 at 02:05 PMAAPG+1.53%06855+1.74%
Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Callbenzinga_article·Aug 21 at 06:07 AMAAPG+1.53%06855+1.74%
Ascentage Pharma appoints Faiçal Miyara chief business officer, names Jim Ziegler chief commercial officerPUBT·Aug 20 at 12:14 PMAAPG+1.53%06855+1.74%
Ascentage Pharma: Revenue up 29% YoY to $44.5M, with global trial progress and strengthened leadershipQuartr·Aug 20 at 05:32 AMAAPG+1.53%06855+1.74%
ASCENTAGE 1H26 Loss Widens to RMB817 million; No Interim DividendAASTOCKS News·Aug 20 at 02:11 AM06855+1.74%
Ascentage Pharma rises 3% in Hong Kong after reporting 29% revenue growthHK Stock Market Update·Aug 20 at 01:57 AM06855+1.74%
Ascentage Pharma posts interim results presentation on 1H 2026 business updatePUBT·Aug 20 at 01:16 AMAAPG+1.53%06855+1.74%
Ascentage Pharma: Revenue up 29%, but net loss widened on higher R&D and selling costs; cash reserves declinedQuartr·Aug 19 at 11:09 PMAAPG+1.53%06855+1.74%
Ascentage Pharma Lifts Revenue, Deepens Losses as U.S. Push and BTK Degrader Trials AdvanceTip Ranks·Aug 19 at 11:07 PMAAPG+1.53%06855+1.74%
